Home
/

Dementia (Vascular)

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 31, 2026
Last updated
May 30, 2026
Key takeaway:

Blood testing for vascular dementia uses LDL, ApoB, Lp(a), and hs-CRP to profile atherogenic burden and vascular inflammation associated with small-vessel disease and cognitive decline. Desirable targets cluster low—LDL under 100 mg/dL, ApoB under 80–90 mg/dL, Lp(a) under 30 mg/L, hs-CRP under 1 mg/L—helping forecast cerebrovascular integrity years before symptoms emerge.

Read more →
Table of contents

Vascular Dementia and the Markers That Trace Brain Vessel Health

Vascular dementia arises when brain blood vessels are damaged, reducing blood flow and disrupting the cells that support thinking. Blood biomarkers make this hidden vascular injury visible, turning complex biology into signals that can be monitored. They capture stress on the vessel lining and small vessels (endothelial dysfunction; sICAM‑1, sVCAM‑1), leakage of the blood–brain barrier (MMP‑9), astroglial responses (GFAP, S100B), and downstream injury to nerve fibers (neurofilament light, NfL). Inflammation and clotting signals (CRP, IL‑6, fibrinogen, homocysteine) reflect systemic forces that drive small‑vessel disease. Together, these markers help detect vascular brain injury earlier, gauge ongoing activity, and separate it from primary Alzheimer‑type changes; pairing vascular signals with amyloid and tau measures (Aβ, p‑tau) clarifies whether cognitive decline is vascular, neurodegenerative, or mixed. In short, vascular dementia biomarkers translate blood into a picture of neurovascular health, enabling risk stratification, tracking over time, and targeted prevention focused on protecting the brain’s circulation (neurovascular unit).

Why Measuring Vascular Risk Matters for Cognition

Vascular dementia blood biomarkers capture how your blood vessels, immune system, and liver-driven lipoproteins are shaping blood flow to the brain. They spotlight atherogenic particle burden (LDL cholesterol and ApoB), inherited risk (Lp[a]), and vascular inflammation (hs‑CRP)—factors that drive small‑vessel disease, microinfarcts, and white‑matter injury that slow thinking and impair gait and mood.In most labs, desirable cut‑points cluster toward the low end: LDL under 100, ApoB under 80–90, Lp(a) under 30, and hs‑CRP under 1. “Typical” mid‑range LDL or ApoB can still permit artery aging, especially if hs‑CRP sits in the middle to high end. Men tend to accrue risk earlier; women’s risk accelerates after menopause. In youth, persistently high ApoB/LDL seeds vascular changes decades before symptoms.When these numbers are low, blood is less injurious to vessel linings, perfusion to deep brain tissue is steadier, and white‑matter pathways are better preserved—making cognitive slowing less likely. Very low lipids can occasionally reflect conditions like hyperthyroidism, malabsorption, or severe illness, sometimes accompanied by weight loss, palpitations, or fatigue; low hs‑CRP simply signals quiet inflammation.Higher values point to more particle entry into vessel walls and active inflammation: small‑artery narrowing, microinfarcts, and white‑matter changes that show up as slower processing, poor multitasking, gait instability, urinary urgency, mood shifts, and a stepwise decline. Elevated Lp(a) adds thrombotic tendency and plaque complexity. Pregnancy can transiently raise lipids and hs‑CRP, while postmenopause levels often rise.Big picture: these markers connect liver metabolism, genetics, and immune tone to cerebrovascular integrity. Alongside blood pressure, glucose, and kidney function, they forecast stroke risk, silent brain injury, and the long‑term trajectory toward vascular dementia—often years before symptoms emerge.

What a Vascular Risk Panel Can and Can't Tell You About Dementia

Dementia (Vascular) blood testing provides insight into the health of your blood vessels and how well your brain is supplied with oxygen and nutrients. Vascular dementia is closely linked to the health of the cardiovascular system, which affects not only cognition but also energy, metabolism, and overall system stability. At Superpower, we test LDL cholesterol, ApoB, Lp(a), and hs-CRP to assess key aspects of vascular health that influence dementia risk.LDL (low-density lipoprotein) is often called “bad cholesterol” because high levels can lead to plaque buildup in arteries, restricting blood flow to the brain. ApoB (apolipoprotein B) is a protein found on LDL particles and provides a more precise count of these cholesterol-carrying particles. Lp(a), or lipoprotein(a), is a genetic variant of LDL that is particularly atherogenic, meaning it can accelerate plaque formation. hs-CRP (high-sensitivity C-reactive protein) is a marker of inflammation, which can damage blood vessels and contribute to both heart disease and vascular dementia.Healthy levels of LDL, ApoB, and Lp(a) support stable blood flow and reduce the risk of small vessel damage in the brain, which is crucial for maintaining cognitive function. Low hs-CRP indicates minimal inflammation, supporting the integrity of blood vessels and reducing the risk of vascular injury that can lead to dementia.Interpretation of these biomarkers can be influenced by age, acute illness, chronic conditions, medications, and even laboratory methods. For example, levels may shift during infections, pregnancy, or with certain therapies, so results are best understood in the context of your overall health.

FAQs

It’s a blood-based risk screen for the vascular causes of cognitive decline. We measure fats that drive artery plaque and signals of vessel inflammation. Superpower tests your blood for LDL cholesterol, ApoB (atherogenic particle count), Lp(a) (inherited lipoprotein), and hs-CRP (high-sensitivity C‑reactive protein). These markers don’t diagnose dementia; they quantify atherosclerosis and inflammation that impair brain blood flow and promote small-vessel disease and strokes.

Because vascular brain injury starts years before symptoms. LDL and ApoB reflect the load of plaque-forming particles; Lp(a) adds inherited risk; hs-CRP captures vascular inflammation. Together they map your cerebrovascular risk, the processes that cause white matter damage, microinfarcts, and post-stroke cognitive decline. Early detection lets you track the biology that drives vascular dementia, not just its late effects.

Yes. With Superpower, our team member can organize a professional blood draw in your home. The sample is processed to measure LDL, ApoB, Lp(a), and hs-CRP, then reported with clear context for vascular brain health.

LDL and ApoB are typically checked every 6–12 months to track atherogenic burden over time. Lp(a) is largely genetic and usually needs a one-time measurement. hs-CRP can fluctuate; confirm elevations with a repeat test in 2–4 weeks when you’re well. More frequent testing may be useful during active risk management, but long-term trends are what matter.

LDL and ApoB shift with metabolic state, weight changes, thyroid and kidney function, diabetes, pregnancy, and certain medications. Lp(a) is genetically set and minimally altered by nonpharmacologic factors. hs-CRP rises with infection, injury, chronic inflammatory disease, and even recent strenuous exercise. Acute illness can transiently distort results; testing when well shows your true baseline.

Fasting 8–12 hours can standardize LDL; ApoB and Lp(a) don’t require fasting. Avoid strenuous exercise and alcohol the day before, and don’t test if you’re acutely ill, as hs-CRP will spike. Hydrate well. Take usual medications unless you’ve been told otherwise. Superpower will provide clear pre-test instructions and measures LDL, ApoB, Lp(a), and hs-CRP from one draw.

References

  1. O'Brien, J. T., & Thomas, A. (2015). Vascular dementia. The Lancet, 386(10004), 1698-1706. https://doi.org/10.1016/S0140-6736(15)00463-8
  2. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144
  3. Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., McNeal, C. J., Moriarty, P. M., Natarajan, P., Nordestgaard, B. G., Parhofer, K. G., Virani, S. S., von Eckardstein, A., Watts, G. F., Stock, J. K., ... Catapano, A. L. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. European Heart Journal, 43(39), 3925-3946. https://doi.org/10.1093/eurheartj/ehac361
  4. Emerging Risk Factors Collaboration, Kaptoge, S., Di Angelantonio, E., Lowe, G., Pepys, M. B., Thompson, S. G., Collins, R., & Danesh, J. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. The Lancet, 375(9709), 132-140. https://doi.org/10.1016/S0140-6736(09)61717-7
  5. Anstey, K. J., Ashby-Mitchell, K., & Peters, R. (2017). Updating the evidence on the association between serum cholesterol and risk of late-life dementia: Review and meta-analysis. Journal of Alzheimer's Disease, 56(1), 215-228. https://doi.org/10.3233/JAD-160826

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey